


## Ventoux Biosciences Launches to Transform Disease Management for Fibrotic Disease

Dupuytren's Disease Impacts Millions of Patients including Company Founder, Pharmaceutical Industry Veteran

SAN DIEGO, CALIFORNIA, UNITED STATES, April 25, 2023 /EINPresswire.com/ -- <u>Ventoux</u> <u>Biosciences</u>, a privately held specialty pharmaceutical company, has launched with a mission to deliver lifechanging therapies for patients with Dupuytren's and related fibrotic diseases. The company initiated preclinical evaluation of its early-stage pipeline, VEN-201 and VEN-202, in Q2 2023.

Dupuytren's disease (palmar fibromatosis) is a common, progressive, debilitating, often painful fibrotic disease impacting hand mobility and function. Limited



Dupuytren's Disease: A Crippling and Under-Treated Fibrotic Disease

noninvasive options exist therefore surgical interventions remain the mainstay of care. Surgical options, while helpful for patients, are known to have high disease recurrence, prolonged recovery times, and potential complications. Disease <u>recurrence can occur in up to 85% of</u> <u>surgeries</u> with overall surgical complication rates up to 39%.

"As a Dupuytren's patient myself, I started Ventoux Biosciences to develop new treatments to slow disease progression and improve outcomes for the millions of patients with mild to severe disease," said Kurt Harrington, Founder & CEO of Ventoux Biosciences. Harrington continues, "My father also has Dupuytren's, which is the most common inherited connective tissue disorder. The emotional driver for starting the company is to bring new options to market to help millions of my fellow patients, including my Dad, as well as for my two teenage sons, should they develop this predominantly genetic disease." "Currently, patients with early Dupuytren's disease have no recourse other than waiting for the disease to progress in order to be eligible for treatment, including hand surgery," said Keith Denkler, MD. Clinical Professor of Plastic Surgery at the University of California San Francisco and member of Ventoux Biosciences Scientific Advisory Board.

Dupuytren's disease is estimated to affect 8.2% of the population worldwide and over 30 million patients in the United States and Europe alone. Ventoux Biosciences is focused on development of treatments that will attenuate fibrosis and reduce inflammation in this under-served patient population.



Kurt Harrington, Ventoux Biosciences Founder & CEO

For more information about Dupuytren's Disease or Ventoux Biosciences, please visit VentouxBio.com.

## ٢٢

As a Dupuytren's patient myself, I started Ventoux Biosciences to develop new treatments to slow disease progression and improve outcomes for the millions of patients with mild to severe disease"


Kurt Harrington

## ###

About Ventoux Biosciences

Founded in 2022 by a Dupuytren's patient with >25 years of Pharmaceutical industry experience, Ventoux Biosciences, Inc is a specialty pharmaceutical company focused on acquiring, in-licensing, developing, and commercializing proprietary products to treat Dupuytren's disease and related fibroproliferative, inflammatory diseases with significant unmet medical need.

Michelle Stansbury Little Penguin PR Michelle@LittlePenguinPR.com Visit us on social media: LinkedIn



This press release can be viewed online at: https://www.einpresswire.com/article/628902693

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.